Document:

Exhibit

EXHIBIT 10.2
EXECUTION VERSION

This AMENDMENT NO. 4 (this “Amendment No. 4”), dated as of March 14, 2017 and entered into by and among Perrigo Finance Unlimited Company (formerly Perrigo Finance PLC), a public unlimited company organized under the laws of Ireland, Perrigo Company PLC, a public limited company organized under the laws of Ireland (together with Perrigo Finance Unlimited Company, the “Term Facility Borrowers”), certain Lenders listed on the signature pages hereto (the “Consenting Lenders”) and JPMorgan Chase Bank, N.A., as administrative agent (in such capacity, the “Administrative Agent”), amends that certain Term Loan Credit Agreement, dated as of December 5, 2014 (as amended by Amendment No. 1, dated as of February 26, 2016, Amendment No. 2, dated as of September 9, 2016, and Amendment No. 3, dated as of December 8, 2016, and as further amended, restated, supplemented, waived or otherwise modified from time to time prior to the date hereof, the “Credit Agreement”), by and among the Term Facility Borrowers, the lenders party thereto, the Administrative Agent and the other agents party thereto.
W I T N E S S E T H :
WHEREAS, each Term Facility Borrower has requested that the Credit Agreement be amended as set forth herein;
WHEREAS, by signing this Amendment No. 4 the Required Lenders have consented to this Amendment No. 4 and to the amendments to the Credit Agreement described in Section 2 below.
NOW, THEREFORE, in consideration of the premises contained herein, the parties hereto agree as follows:
1.Defined Terms; References. Except as otherwise defined in this Amendment No. 4, terms defined in the Credit Agreement are used herein (including the recitals hereto) as defined therein. On and after the Amendment Effective Date (as defined below), each reference in the Credit Agreement to “this Agreement,” “hereunder,” “hereof” or words of like import referring to the Credit Agreement shall mean and be a reference to the Credit Agreement, as amended by this Amendment No. 4.
2.Amendments. The Administrative Agent and each Consenting Lender (in the aggregate representing Required Lenders) hereby consents to amend:
(a) Section 1.01 of the Credit Agreement by adding the following defined term in proper alphabetical order:
“Tysabri Sale” means sale by the Company or one or more of its Subsidiaries of the rights to receive contingent payments on Tysabri® and related compounds under the Asset Purchase Agreement by and among Elan Pharma International, Elan Pharmaceuticals, Inc. and Biogen Idec International Holding Ltd. dated February 5, 2013.
(b)  Section 1.04 of the Credit Agreement by adding the following at the end thereof:
13183306.5

“Until such time as the 2016 Form 10-K is filed with the SEC, any calculation of Consolidated Total Assets or Consolidated Total Tangible Assets will be based upon the information in the Company’s Form 10-Q for the Fiscal Quarter ended October 1, 2016.”
(c)    Section 5.01(a) of the Credit Agreement by amending and restating it in its entirety as follows:
(a)    within 90 days (or such earlier date as the Company may be required to file its applicable annual report on Form 10-K by the rules and regulations of the SEC) after the end of each Fiscal Year of the Company ending after the Effective Date (or, in respect of the Fiscal Year of the Company ending on or about December 31, 2016 (the “2016 10-K”), within the earlier of 180 days after the end of such Fiscal Year and 90 days after the date of any notice of default is given under any Material Indebtedness arising from the failure to timely provide the 2016 10-K), its audited consolidated balance sheet and related statements of operations, stockholders’ equity and cash flows as of the end of and for such year, setting forth in each case in comparative form the figures for the previous Fiscal Year, if any, all reported on by Ernst and Young LLP or other independent public accountants of recognized national standing (without a “going concern” or like qualification or exception and without any qualification or exception as to the scope of such audit) to the effect that such consolidated financial statements present fairly in all material respects the financial condition and results of operations of the Company and its consolidated Subsidiaries on a consolidated basis in accordance with GAAP consistently applied (except as may be indicated in the notes thereto);
(d)  Section 5.01(b) of the Credit Agreement by amending and restating it in its entirety as follows:
 (b)    within 45 days (or such earlier date as the Company may be required to file its applicable quarterly report on Form 10-Q by the rules and regulations of the SEC) after the end of each of the first three Fiscal Quarters of each Fiscal Year of the Company, beginning with the first Fiscal Quarter ending after the Effective Date (or, in respect of the Fiscal Quarter of the Company ending on or about March 31, 2017 (the “Q1 2017 10-Q”), within 90 days after the end of such Fiscal Quarter), its consolidated balance sheet and related statements of operations, stockholders’ equity and cash flows as of the end of and for such Fiscal Quarter and the then elapsed portion of the Fiscal Year, setting forth in each case in comparative form the figures for the corresponding period or periods of (or, in the case of the balance sheet, as of the end of) the previous Fiscal Year, if any, all certified by one of its Financial Officers as presenting fairly in all material respects the financial condition and results of operations of the Company and its consolidated Subsidiaries on a consolidated basis in accordance with GAAP consistently applied, subject to normal year-end audit adjustments and the absence of footnotes;
(e)  Section 6.09(c) of the Credit Agreement by replacing the word “ and” with “,”;
(f)  Section 6.09(d) of the Credit Agreement by replacing “.” with “ and”; 
(g)  Section 6.09 of the Credit Agreement by adding a new subclause (e) thereof as follows:

13183306.5

2

 “(e) prohibit the Tysabri Sale.”
(h)  Section 6.10 of the Credit Agreement by amending and restating subclause (iii) in the second paragraph thereof as follows:
“(iii) beginning with the Fiscal Quarter ended on or about March 31, 2016, the Company will not permit the Leverage Ratio to exceed 4.75 to 1.0 as of the last day of any such Fiscal Quarter of the Company, except that if the Tysabri Sale occurs on or before the last day of the Fiscal Quarter ended on or about March 31, 2017, then for the Fiscal Quarter ended on or about March 31, 2017, the Company may permit the Leverage Ratio to exceed 4.75 to 1.0 but may not permit the Leverage Ratio to exceed 6.0 to 1.0 as of the last day of such Fiscal Quarter,”.
(i)  Section 6.10 of the Credit Agreement by amending and restating subclause (iv) in the second paragraph thereof as follows:
“(iv) beginning with the Fiscal Quarter ended on or about June 30, 2017, the Company will not permit the Leverage Ratio to exceed 4.50 to 1.0 as of the last day of any such Fiscal Quarter of the Company, except that if the Tysabri Sale occurs and the Q1 2017 10-Q has not been filed with the SEC on or prior to May 16, 2017, then for the Fiscal Quarter ended on or about June 30, 2017, the Company may permit the Leverage Ratio to exceed 4.50 to 1.0 but may not permit the Leverage Ratio to exceed 6.0 to 1.0 as of the last day of such Fiscal Quarter,”.
(j)    Article VII of the Credit Agreement by amending and restating clause (e)(i) thereof as follows:
“except with respect to the 2016 10-K and the Q1 2017 10-Q for which there shall be no period of grace, any Loan Party shall fail to observe or perform any covenant, condition or agreement contained in Section 5.01 and such failure shall continue unremedied for a period of five days (provided such time period shall be ten days with respect to compliance certificates required to be delivered pursuant to Section 5.01(c)) after notice thereof from the Administrative Agent to the Term Facility Borrowers (which notice will be given at the request of any Lender);”
(k)    Article VII of the Credit Agreement by amending clause (g) thereof by adding a proviso at the end thereof as follows:
“; provided further that this clause (g) shall not apply to any default occurring under Material Indebtedness arising solely as a result of the Company’s failure to timely provide either the 2016 10-K or the Q1 2017 10-Q unless and until such failure enables or permits, after the giving of notice and the expiration of any applicable grace periods, the holder or holders of such Material Indebtedness or any trustee or agent on its or their behalf to cause such Material Indebtedness to become due, or to require the prepayment, repurchase, redemption or defeasance thereof, prior to its scheduled maturity.”
3. Representations and Warranties; Loan Document. Each Term Facility Borrower hereby represents and warrants that as of the date hereof (a) the representations and warranties of the Loan Parties set forth in the Loan Documents are true and correct in all material respects (except that any representation or warranty which is already qualified as to materiality or by reference to Material Adverse Effect is true and correct in all respects) on and as of such date, with the same effect as if made on and as of such date (other than those representations and warranties that by their terms 
13183306.5

3

expressly relate to an earlier date, in which case such representations and warranties were true and correct in all material respects as of such earlier date) and (b) no Default or Event of Default has occurred and is continuing. This Amendment No. 4 is a “Loan Document,” as defined in the Credit Agreement.
4. Conditions.    The amendments contained in Section 2 of this Amendment No. 4 shall become effective on the date (the “Amendment Effective Date”) on which each of the following conditions shall have been satisfied:
(a)The Administrative Agent shall have received counterparts of this Amendment No. 4 duly executed and delivered by each Term Facility Borrower, Consenting Lenders constituting the Required Lenders and the Administrative Agent.
(b)The representations and warranties of each Loan Party set forth in Section 3 above are true and correct on and as of the Amendment Effective Date.
(c)Each Term Facility Borrower shall have paid all fees (including the Consent Fees payable on the Amendment Effective Date) and expenses for which invoices have been presented on or prior to the Amendment Effective Date, including reasonable legal fees and disbursements of counsel to the Administrative Agent.
5.     Consent Fees.  Each Term Facility Borrower agrees to pay, or cause to be paid, to the Administrative Agent, for the account of each Consenting Lender, (i) on the Amendment Effective Date a consent fee equal to 0.025% of the sum of the aggregate amount of outstanding Loans of such Lender and (ii) on May 16, 2017, if the Company has not filed the 2016 10-K with the SEC before such date, an additional consent fee equal to 0.025% of the sum of the aggregate amount of outstanding Loans of such Lender on such date (collectively, the “Consent Fees”).
6.    Continuing Effect; No Other Amendments; Reaffirmation. Except as expressly provided herein, all of the terms and provisions of the Credit Agreement are and shall remain in full force and effect. The amendments provided for herein are limited to the specific subsection of the Credit Agreement specified herein and shall not constitute an amendment of, or an indication of the Administrative Agent’s or the Lenders’ willingness to amend any other provisions of the Credit Agreement. Each Term Facility Borrower hereby acknowledges and agrees that, after giving effect to this Amendment No. 4, except as expressly set forth in this Amendment No. 4, all of its respective obligations and liabilities under the Loan Documents (including, without limitation, the Guaranty executed by Perrigo Company PLC) to which it is a party are reaffirmed, and remain in full force and effect. The execution, delivery and performance of this Amendment No. 4 shall not constitute a waiver of any provision of, or operate as a waiver of any right, power or remedy of any Agent or Lender under, the Credit Agreement or any of the other Loan Documents.
7. Expenses. Each of the Term Facility Borrowers agrees to pay and reimburse the Administrative Agent for all its reasonable costs and out-of-pocket expenses incurred in connection 
13183306.5

4

with the preparation and delivery of this Amendment No. 4, including, without limitation, the reasonable fees and disbursements of counsel to the Administrative Agent.
8. Headings. Section headings herein and in the Loan Documents are included for convenience of reference only and shall not affect the interpretation of this Amendment No. 4 or any Loan Document.
9. Counterparts. This Amendment No. 4 may be executed in counterparts (and by different parties hereto on different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract. Delivery of an executed counterpart of a signature page of this Amendment No. 4 by email or facsimile transmission or other electronic means shall be effective as delivery of a manually executed counterpart of this Agreement.
10. GOVERNING LAW. THIS AMENDMENT NO. 4 SHALL BE CONSTRUED IN ACCORDANCE WITH AND GOVERNED BY THE LAW OF THE STATE OF NEW YORK. SECTIONS 9.09 AND 9.10 OF THE CREDIT AGREEMENT ARE INCORPORATED BY REFERENCE HEREIN MUTATIS MUTANDIS.
[remainder of page intentionally left blank]

13183306.5

5

IN WITNESS WHEREOF, the parties hereto have caused this Amendment No. 4 to be duly executed and delivered by their respective authorized officers as of the day and year first above written.

	
		
	PERRIGO FINANCE UNLIMITED COMPANY,

	as Term Facility Borrower

	 
	 

	By:
	/s/ Lou Cherico

	 
	Name: Lou Cherico

	 
	Title:    VP, Treasurer

	 
	 

	
		
	PERRIGO COMPANY PLC,

	as Term Facility Borrower

	 
	 

	By:
	/s/ Lou Cherico

	 
	Name: Lou Cherico

	 
	Title:    VP, Treasurer

	 
	 

[Perrigo Term Amendment No. 4]

	
		
	JPMORGAN CHASE BANK, N.A.,

	as Administrative Agent

	 
	 

	By:
	/s/ Krys Szremski

	 
	Name: Krys Szremski

	 
	Title:    Executive Director

	 
	 

    
    

[Signature Page - Term Amendment No.4]

	
		
	JPMORGAN CHASE BANK, N.A.,

	as Lender

	 
	 

	By:
	/s/ Krys Szremski

	 
	Name: Krys Szremski

	 
	Title:    Executive Director

	 
	 

[Signature Page - Term Amendment No.4]

	
		
	BARCLAYS BANK PLC, as Lender

	 

	By:
	/s/ Evan Moriarty

	 
	Name: Evan Moriarty

	 
	Title:    Assistant Vice President

	 
	 

[Signature Page - Term Amendment No.4]

	
		
	BANK OF AMERICA, N.A., as Lender

	 

	By:
	/s/ Joseph L. Corah

	 
	Name: Joseph L. Corah

	 
	Title:    Director

	 
	 

If a second signature is necessary:
	
		
	[    ], as Lender

	 

	By:
	 

	 
	Name: 

	 
	Title: 

	 
	 

[Signature Page - Term Amendment No.4]

	
		
	HSBC BANK USA, N.A., as Lender

	 

	By:
	/s/ Andrew Bicker

	 
	Name: Andrew Bicker

	 
	Title:    Director

	 
	 

[Signature Page - Revolver Amendment No.4]

	
		
	WELLS FARGO BANK NATIONAL ASSOCIATION, as

	Lender

	 

	By:
	/s/ Kirk Tesch

	 
	Name: Kirk Tesch

	 
	Title:    Managing Director

	 
	 

 

[Signature Page - Term Amendment No.4]

	
		
	CITIBANK, N.A., as Lender

	 

	By:
	/s/ Laura Fogarty

	 
	Name: Laura Fogarty

	 
	Title:    Vice President

	 
	 

[Signature Page - Term Amendment No.4]

	
		
	CITIZENS BANK, N.A., as Lender

	 

	By:
	/s/ Darran Wee

	 
	Name: Darran Wee

	 
	Title:    Senior Vice President

	 
	 

[Signature Page - Term Amendment No.4]

	
		
	MIZUHO BANK, LTD.

	as Lender

	 

	By:
	/s/ Bertram H. Tang

	 
	Name: Bertram H. Tang

	 
	Title:    Authorized Signatory

	 
	 

[Signature Page - Term Amendment No.4]

	
		
	CREDIT SUISSE AG, CAYMAN ISLANDS 

	BRANCH, as Lender

	 

	By:
	/s/ Christopher Day

	 
	Name: Christopher Day

	 
	Title:    Authorized Signatory

	 
	 

	By:
	/s/ Joan Park

	 
	Name: Joan Park

	 
	Title:    Authorized Signatory

`

[Signature Page - Term Amendment No.4]

	
		
	BNP PARIBAS, as Lender

	 

	By:
	/s/ Michael Pearce

	 
	Name: Michael Pearce

	 
	Title:    Managing Director

	 
	 

	
		
	BNP PARIBAS, as Lender

	 

	By:
	/s/ Michael Hoffman

	 
	Name: Michael Hoffman

	 
	Title:    Director

	 
	 

[Signature Page - Revolver Amendment No.4]

	
		
	THE NORTHERN TRUST COMPANY, as Lender

	 

	By:
	/s/ Wicks Barkhausen

	 
	Name: Wicks Barkhausen

	 
	Title:  Vice President

	 
	 

[Signature Page - Term Amendment No.4]

	
		
	SUMITOMO MITSUI BANKING CORPORATION, as Lender

	 

	By:
	/s/ James D. Weinstein

	 
	Name: James D. Weinstein

	 
	Title:    Managing Director

	 
	 

[Signature Page - Term Amendment No.4]

	
		
	BANK HAPOALIM B.M., as Lender

	Lender

	 

	By:
	/s/ Yael Weinstock-Shemesh

	 
	Name: Yael Weinstock-Shemesh

	 
	Title:       Senior Vice President

	 
	        Head of the Israeli Business Group

                 If a second signature is necessary:

	
		
	BANK HAPOALIM B.M., as Lender

	Lender

	 

	By:
	/s/ Tal Shapaizer

	 
	Name:    Tal Shpaizer

	 
	Title:        Vice President

	 
	        Israeli Business Group

[Signature Page - Term Amendment No.4]

	
		
	ING Belgium NV/SA,

	as Lender

	 
	 

	By:
	/s/ Ann Larcher

	 
	Name:    Ann Larcher

	 
	Title: Head of Policies, Decisions & Standard Lending

	 
	 

	ING Belgium NV/SA

	as Lender

	 
	 

	By:
	/s/ Johan Vanhoyland

	 
	Name: Johan Vanhoyland

	 
	Title:    Managing Director

	 
	Sector Head General Industries & Pharmaceuticals

  

  [Perrigo Term Amendment No.4]

                   	
		
	PNC BANK, NATIONAL ASSOCIATION, as

	Lender

	 

	By:
	/s/ Sommar M. Bainbridge

	 
	Name: Sommar M. Bainbridge

	 
	Title:    Senior Vice President

	 
	 

[Signature Page - Term Amendment No.4]

	
		
	U.S. BANK NATIONAL ASSOCIATION, as Lender

	 

	By:
	/s/ Jeffrey S. Johnson

	 
	Name: Jeffrey S. Johnson

	 
	Title:    Senior Vice President

	 
	 

[Signature Page - Term Amendment No.4]

	
		
	FIFTH THIED BANK, as Lender

	 

	By:
	/s/ Nathaniel E. Sher

	 
	Name: Nathaniel E. Sher

	 
	Title:    Vice President

	 
	 

[Signature Page - Term Amendment No.4]Exhibit

Exhibit 10.1

May 14, 2015

Megan Schoeps

Dear Megan,

On behalf of Bellerophon Therapeutics ("the Company"), I am pleased to offer you employment as Assistant Controller commencing on June 1, 2015 (Effective Date). The purpose of this letter is to summarize the salient terms of your employment with the Company.

1. DUTIES

• You will report directly to David Abrams, Treasurer. You will perform duties customary to the Assistant Controller position and such other duties that may reasonably be assigned from time to time by the Company.

2. COMPENSATION, ANNUAL AND LONG-TERM INCENTIVES

• Your annual base salary will be $ 145,000.00 ("Base Compensation"), payable on a bi-weekly cycle. Your base compensation will be subject to an annual review by the Company. Naturally, total compensation, including base compensation and bonus, is contingent upon your continued employment with the Company and will be paid as earned.

• For each full calendar year during the period of your service with Bellerophon Therapeutics (the "Employment Period"), you will be eligible to receive, on the same basis as other employees of Bellerophon, a performance award comprised of annual bonus and stock options based on the achievement of various goals. For the 2015 performance year, you will be eligible to receive a performance award at
the target level of 25% of your Base Compensation (comprised of 15% cash bonus and 10% stock options).

• The Company shall grant you the option to purchase 2,000 shares of Bellerophon common stock (such shares, including any securities into which such shares are changed or for which such shares are exchanged, the "Common Stock") at a per share exercise price equal to the fair value of the Common Stock
at the date you commence employment with the company (as determined by the Board of Directors of the Company) (the "Option"). The Option shall be evidenced by the form of Stock Option Agreement provided to you.

3. BENEFITS

• ·During the Employment Period, you will be entitled to participate, on the same basis as other employees of the Company, in any medical and dental benefit, disability or life insurance plans maintained by the Company for the benefit of its employees. Your participation in such plans shall be subject to all terms and
conditions of such plans, including your ability to satisfy any medical or health requirements imposed by the underwriters of any insurance policies paid to fund the plans.

• You will be entitled to participate, on the same basis as other employees of the Company, in the Company's 40l(k) plan, with such participation subject to all terms and conditions of such plans, including any eligibility waiting period.

53 Frontage Road, Suite 301, Hampton, NJ 08827 l 908-574-4770 l bellerophon.com

• You will be eligible to receive, on the same basis as other similarly situated employees of the Company, any other employee benefits, including ten (10) paid holidays, twenty (20) paid time off (PTO) days.

A copy of the current benefit plans of the company are attached to this letter.

4. OTHER TERMS AND CONDITIONS OF EMPLOYMENT

• You will be required to provide proof of your eligibility to work in the United States. On your first day of work, you must supply us with a completed Employment Verification Form (Form I-9) with required supporting documents. While you are employed by the Company, you will be expected to devote your
full working time, energy, skill and experience in the performance of your duties, which may be redefined or modified by the Company from time to time.

• The Company's employment offer is contingent upon your successful completion of a background check, drug screen and completed reference check.

• By signing this letter you agree that this offer is personal and confidential and should not be discussed with any other employees in the Company.

• Your employment with the Company is at will. You or the Company may terminate the employment relationship at any time with or without cause. This letter is not a contract, nor a promise of employment for any specific duration. The above salary information is communicated as a yearly rate solely for your
information and does not constitute a promise of employment for any fixed term. This letter and its enclosures constitute the final and complete agreement with respect to your employment and supersede any prior or contemporaneous discussions, representations or commitments. The letter cannot be modified
except in writing signed by both parties.

5. OBLIGATIONS TO PRIOR EMPLOYER

• By accepting this offer, you represent that you are not a party to and have not been a party to any employment agreement which could interfere with your employment with Bellerophon, except those which you identify to me and, to the extent possible, submit copies of the agreement. This offer is contingent upon a review of these agreements, prior to your starting date, to insure that you are under no legal restraints with regard to your employment with Bellerophon.

If you agree with the terms and conditions of this offer, please indicate below by signing and dating this letter in the spaces provided and return an executed copy to me.

We are very much looking forward to having you join our team.

Sincerely,

/s/ David Abrams

David Abrams
Treasurer
Bellerophon Therapeutics

ACCEPTANCE:

53 Frontage Road, Suite 301, Hampton, NJ 08827 l 908-574-4770 l bellerophon.com

	
			
	/s/ Megan Schoeps
	 
	5/18/15

	Employee Signature verifying review    and acceptance of above information

	 
	Date

53 Frontage Road, Suite 301, Hampton, NJ 08827 l 908-574-4770 l bellerophon.com

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00268-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00268-of-00352.parquet"}]]